Hims & Hers Health (NYSE:HIMS) Stock Price Up 5.8%

Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report)’s share price rose 5.8% on Wednesday . The stock traded as high as $23.47 and last traded at $23.31. Approximately 3,429,492 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 6,837,543 shares. The stock had previously closed at $22.04.

Analyst Upgrades and Downgrades

Several research firms have recently commented on HIMS. Imperial Capital upgraded Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price target for the company in a research report on Wednesday, February 28th. Canaccord Genuity Group started coverage on Hims & Hers Health in a report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 target price for the company. Canaccord Genuity Group raised their price target on Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, May 22nd. SVB Leerink initiated coverage on Hims & Hers Health in a research note on Monday, February 26th. They issued a “market perform” rating and a $10.00 price target on the stock. Finally, Bank of America lifted their target price on Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Thursday. Seven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.43.

View Our Latest Report on Hims & Hers Health

Hims & Hers Health Stock Performance

The stock’s fifty day simple moving average is $15.60 and its two-hundred day simple moving average is $12.42. The company has a market capitalization of $5.10 billion, a price-to-earnings ratio of -2,382.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMSGet Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.02 by $0.03. The business had revenue of $278.20 million during the quarter, compared to analysts’ expectations of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The firm’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.05) EPS. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Soleil Boughton sold 2,503 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $15.65, for a total transaction of $39,171.95. Following the completion of the transaction, the insider now directly owns 166,866 shares in the company, valued at $2,611,452.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Soleil Boughton sold 2,503 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $15.65, for a total value of $39,171.95. Following the transaction, the insider now owns 166,866 shares in the company, valued at $2,611,452.90. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Lynne Chou O’keefe sold 10,044 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $15.52, for a total value of $155,882.88. The disclosure for this sale can be found here. Insiders sold 951,004 shares of company stock worth $16,188,821 over the last three months. 17.71% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds have recently modified their holdings of the business. Victory Capital Management Inc. increased its position in shares of Hims & Hers Health by 23.0% during the 4th quarter. Victory Capital Management Inc. now owns 18,348 shares of the company’s stock worth $163,000 after purchasing an additional 3,429 shares during the last quarter. Graham Capital Management L.P. boosted its stake in shares of Hims & Hers Health by 39.4% during the 3rd quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock worth $2,141,000 after acquiring an additional 96,277 shares during the period. Forerunner Ventures Management LLC bought a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $86,836,000. Swiss National Bank boosted its stake in shares of Hims & Hers Health by 9.2% during the 3rd quarter. Swiss National Bank now owns 309,200 shares of the company’s stock worth $1,945,000 after acquiring an additional 26,100 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Hims & Hers Health by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after acquiring an additional 428,671 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Further Reading

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.